Sign up Australia
Proactive Investors - Run By Investors For Investors

Genetic Technologies exceeds fiscal 2012 revenues for DNA technology

Genetic Technologies exceeds fiscal 2012 revenues for DNA technology

Genetic Technologies (ASX: GTG) has already surpassed gross revenues generated by its non-coding DNA technology licensing program in the 2012 financial year in just the first five months of the 2013 financial year.

Importantly, the non-dilutive funding has added substantially to the company’s cash reserves as at 30 November 2012, which exceeded $7.5 million.

The intellectual property out-licensing program provides a contracted annuity stream of $5.5 million through to 2015.

Over 65 licences have been awarded, generating around $70 million in revenue so far, with $13.5 million of that secured from nine contracts in 2011 alone – marking a record licensing year for Genetic.

The company has several patent families protecting the use of its non-coding DNA for genetic analysis.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

View full GTG profile View Profile

Genetic Technologies Timeline

Newswire
March 06 2015

Related Articles

Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.
1534822132_cadoux.jpg
August 21 2018
The company aims to revolutionise the HPA production process, eschewing the laborious bauxite-sourced method.
syringe
June 21 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use